Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors

NCT02444884 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT02444884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02444884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2008
Completion date
December 31, 2011
Enrollment
54 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma, unspecified childhood solid tumor, excluding cns